Table 1.
Clinicopathologic Features of DLBCL Patients with High or Low p-AKT Expression
| Variable | DLBCL |
GCB-DLBCL |
ABC-DLBCL |
||||||
|---|---|---|---|---|---|---|---|---|---|
| p-AKThigh (n = 127) | p-AKTlow (n = 395) | P | p-AKThigh (n = 61) | p-AKTlow (n = 204) | P | p-AKThigh (n = 66) | p-AKTlow (n = 184) | P | |
| Age, years | |||||||||
| <60 | 61 (48.0) | 163 (41.3) | 0.18 | 35 (57.4) | 99 (48.5) | 0.25 | 26 (39.4) | 59 (32.1) | 0.29 |
| ≥60 | 66 (52.0) | 232 (58.7) | 26 (42.6) | 105 (51.5) | 40 (60.6) | 125 (67.9) | |||
| Sex | |||||||||
| Male | 73 (57.5) | 228 (57.7) | 1.0 | 37 (60.7) | 115 (56.4) | 0.66 | 36 (54.5) | 110 (59.8) | 0.47 |
| Female | 54 (42.5) | 167 (42.3) | 24 (39.3) | 89 (43.6) | 30 (45.5) | 74 (40.2) | |||
| Stage | |||||||||
| I/II | 51 (42.1) | 186 (48.4) | 0.25 | 27 (47.4) | 111 (56.1) | 0.29 | 24 (37.5) | 70 (39.1) | 0.88 |
| III/IV | 70 (57.9) | 198 (51.6) | 30 (52.6) | 87 (43.9) | 40 (62.5) | 109 (60.9) | |||
| B-symptoms | |||||||||
| Absence | 75 (62.0) | 244 (65.2) | 0.51 | 43 (75.4) | 130 (67.7) | 0.33 | 32 (50.0) | 109 (62.3) | 0.1 |
| Presence | 46 (38.0) | 130 (34.8) | 14 (24.6) | 62 (32.3) | 32 (50.0) | 66 (37.7) | |||
| LDH level | |||||||||
| Normal | 45 (38.8) | 143 (39.1) | 1.0 | 22 (39.3) | 79 (42.2) | 0.76 | 23 (38.3) | 63 (36.6) | 0.88 |
| Elevated | 71 (61.2) | 223 (60.9) | 34 (60.7) | 108 (57.8) | 37 (61.7) | 109 (63.4) | |||
| Number of extranodal sites | |||||||||
| 0–1 | 84 (70.0) | 298 (78.2) | 0.085 | 42 (73.7) | 154 (79.4) | 0.37 | 42 (66.7) | 138 (76.7) | 0.13 |
| ≥2 | 36 (30.0) | 83 (21.8) | 15 (26.3) | 40 (20.6) | 21 (33.3) | 42 (23.3) | |||
| ECOG score | |||||||||
| 0–1 | 92 (81.4) | 298 (84.2) | 0.47 | 44 (84.6) | 153 (86.0) | 0.82 | 48 (78.7) | 138 (81.7) | 0.7 |
| ≥2 | 21 (18.6) | 56 (15.8) | 8 (15.4) | 25 (14.0) | 13 (21.3) | 31 (18.3) | |||
| Tumor size, cm | |||||||||
| <5 | 49 (57.6) | 173 (57.5) | 1.0 | 19 (51.4) | 94 (60.3) | 0.36 | 30 (62.5) | 76 (54.3) | 0.4 |
| ≥5 | 36 (42.4) | 128 (42.5) | 18 (48.6) | 62 (39.7) | 18 (37.5) | 64 (45.7) | |||
| IPI score | |||||||||
| 0–2 | 71 (57.3) | 243 (63.6) | 0.24 | 38 (63.3) | 136 (69.7) | 0.35 | 33 (51.6) | 100 (55.6) | 0.66 |
| 3–5 | 53 (42.7) | 139 (36.4) | 22 (36.7) | 59 (30.3) | 31 (48.4) | 80 (44.4) | |||
| Therapy response | |||||||||
| CR | 92 (72.4) | 303 (76.7) | 0.34 | 42 (68.9) | 155 (76.0) | 0.32 | 50 (75.8) | 141 (76.6) | 0.87 |
| PR | 19 | 48 | 8 | 24 | 11 | 24 | |||
| SD | 7 | 15 | 4 | 10 | 3 | 5 | |||
| PD | 9 | 29 | 7 | 15 | 2 | 14 | |||
Data are expressed as n (%) unless otherwise indicated. For therapy response, P values were calculated as CR versus other responses. Percentages were calculated from the total number of patients whose data were available for the characteristic of interest. Not all patients had data available for every characteristic.
ABC, activated B-cell–like; CR, complete response; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell–like; IPI, international prognostic index; LDH, lactate dehydrogenase; p-AKThigh, high levels (≥70%) of phospho-AKT expression; p-AKTlow, low levels (<70%) of phospho-AKT expression; PD, progressive disease; PR, partial response; SD, stable disease.